Gemphire Therapeutics (NASDAQ:GEMP) was upgraded by stock analysts at ValuEngine from a “hold” rating to a “buy” rating in a report released on Thursday, ValuEngine reports.
Several other research firms also recently issued reports on GEMP. Laidlaw raised shares of Gemphire Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, June 27th. Zacks Investment Research downgraded shares of Gemphire Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, May 2nd. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Gemphire Therapeutics presently has an average rating of “Hold” and a consensus price target of $14.90.
Shares of GEMP stock traded down $0.04 during trading hours on Thursday, hitting $0.61. 171,780 shares of the company’s stock traded hands, compared to its average volume of 558,445. The firm has a 50 day moving average price of $0.80. The stock has a market cap of $8.71 million, a PE ratio of -0.36 and a beta of 2.89. Gemphire Therapeutics has a 12 month low of $0.57 and a 12 month high of $7.62.
Gemphire Therapeutics (NASDAQ:GEMP) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.27) earnings per share (EPS) for the quarter.
Gemphire Therapeutics Company Profile
Gemphire Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy.
Featured Story: Index Funds
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Gemphire Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.